Nodular regenerative hyperplasia after treatment with trastuzumab emtansine

Journal of Clinical Oncology

Volumn 34, Issue 3, 2016, Pages e9-e12

  Force, Jeremy ^a   Saxena, Romil ^a   Schneider, Bryan P ^a   Storniolo, Anna M ^a   Sledge, George W ^a   Chalasani, Naga ^a   Vuppalanchi, Raj ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALVESPIMYCIN; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; ENOXAPARIN; FLUOROURACIL; GEMCITABINE; LAPATINIB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PERTUZUMAB; PICTILISIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VINCRISTINE; MAYTANSINE; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; ASCITES; AXILLARY LYMPH NODE DISSECTION; BACTERIAL PERITONITIS; BREAST CARCINOMA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS VARICES; FATTY LIVER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LABORATORY TEST; LIVER BIOPSY; LOADING DRUG DOSE; LYMPH NODE DISSECTION; MIDDLE AGED; NODULAR HYPERPLASIA; NODULAR REGENERATIVE HYPERPLASIA; PARTIAL MASTECTOMY; PHYSICAL EXAMINATION; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; SEROLOGY; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMICALLY INDUCED; DRUG EFFECTS; HYPERPLASIA; LIVER; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; HYPERPLASIA; HYPERTENSION, PORTAL; LIVER; MAYTANSINE; MIDDLE AGED;

EID: 84955616018     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.8543     Document Type: Article

References (16)

1. Girish S, Gupta M, Wang B, et al: Clinical pharmacology of trastuzumab emtansine (T-DM1): An antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69:1229-1240, 2012
2. Sun X, Widdison W, Mayo M, et al: Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 22:728-735, 2011
3. Zheng B, Fuji RN, Elkins K, et al: In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther 8:2937-2946, 2009
4. Gupta S, Bhattacharyya B: Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem 253:41-47, 2003
5. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
6. Burris HA 3rd, Rugo HS, Vukelja SJ, et al: Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) -positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405, 2011
7. Krop IE, Beeram M, Modi S, et al: Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704, 2010
8. Krop IE, LoRusso P, Miller KD, et al: A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30:3234-3241, 2012
9. Shen BQ, Bumbaca D, Saad O, et al: Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): An emphasis on preclinical and clinical catabolism. Curr Drug Metab 13:901-910, 2012
10. Henderson LA, Baynes JW, Thorpe SR: Identification of the sites of IgG catabolism in the rat. Arch Biochem Biophys 215:1-11, 1982
11. Wright A, Sato Y, Okada T, et al: In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 10:1347-1355, 2000
12. Cassady JM, Chan KK, Floss HG, et al: Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo) 52:1-26, 2004
13. Remillard S, Rebhun LI, Howie GA, et al: Antimitotic activity of the potent tumor inhibitor maytansine. Science 189:1002-1005, 1975
14. Beeram M, Krop IE, Burris HA, et al: A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 118:5733-5740, 2012
15. Foster JM, Litwin A, Gibbs JF, et al: Diagnosing regenerative nodular hyperplasia, the "great masquerader" of liver tumors. J Gastrointest Surg 10:727-733, 2006
16. Srinivasan S, Parsa V, Liu CY, et al: Trastuzumab-induced hepatotoxicity. Ann Pharmacother 42:1497-1501, 2008